Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06284460
Title	Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Recruitment	Withdrawn
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	M.D. Anderson Cancer Center
Indications	myelodysplastic/myeloproliferative neoplasm myelodysplastic syndrome myeloproliferative neoplasm chronic myelomonocytic leukemia
Therapies	ASTX029 ASTX029 + Decitabine and Cedazuridine
Age Groups:	adult \| senior
Covered Countries	USA